Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.09.2023 | Case report

Iodine-131/lenvatinib/sorafenib

Various toxicities and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Buenaventura DC, et al. Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report. International Journal of Endocrinology and Metabolism 21: No. 3, Jul 2023. Available from: URL: https://brieflands.com/articles/ijem-136900.pdf Buenaventura DC, et al. Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report. International Journal of Endocrinology and Metabolism 21: No. 3, Jul 2023. Available from: URL: https://​brieflands.​com/​articles/​ijem-136900.​pdf
Metadaten
Titel
Iodine-131/lenvatinib/sorafenib
Various toxicities and lack of efficacy: case report
Publikationsdatum
01.09.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-45874-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Nivolumab

Case report

Abemaciclib